ArticleNature2025
SuFEx-based antitubercular compound irreversibly inhibits Pks13.
Abstract read
In one paragraph
Article in Nature, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Genetic and pharmacological inactivation of peptidoglycan remodeling increases antibiotic susceptibility of vancomycin-resistant Enterococcus faecium.Nature communications · 2026Article
- Large-Scale Chemical-Genetic Interaction Profiling Identifies a Small-Molecule Inhibitor ofACS infectious diseases · 2026Article
- Minimal Computational Framework for Systematic Identification of Antimicrobial Targets.bioRxiv : the preprint server for biology · 2026Article
- Integrating chemical, genetic, and feasibility assessments for anti-tubercular target validation.EMBO molecular medicine · 2026Review
- Adaptive immunity shapes baseline physiology ofbioRxiv : the preprint server for biology · 2026Article
- Genetic and pharmacological inactivation of peptidoglycan remodeling increases antibiotic susceptibility of vancomycin-resistantbioRxiv : the preprint server for biology · 2026Article
- Bifunctional Aziridines from Photochemically Generated FSOAngewandte Chemie (International ed. in English) · 2026Article
- Breaking the barrier: from biosynthetic inhibition to multidimensional modulation of the mycobacterial cell wall in tuberculosis therapy.Frontiers in pharmacology · 2026Review
- Navigating the Lipid Landscape: The Role of Fatty Acid Synthase in Neural Stem Cell Fate and Central Nervous System Function.Molecular neurobiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
45 authors.
Inna V Krieger *Department of Biochemistry and Biophysics, Texas A&M University, College Station, TX, USA.ORCID 0000-0001-7144-3069
Paridhi Sukheja *Calibr-Skaggs Institute for Innovative Medicines, A Division of Scripps Research, La Jolla, CA, USA.
Baiyuan Yang *Calibr-Skaggs Institute for Innovative Medicines, A Division of Scripps Research, La Jolla, CA, USA.
Su TangDepartment of Biochemistry and Biophysics, Texas A&M University, College Station, TX, USA.
Daniel SelleDepartment of Biochemistry and Biophysics, Texas A&M University, College Station, TX, USA.ORCID 0009-0002-1725-0463
Ashley WoodsCalibr-Skaggs Institute for Innovative Medicines, A Division of Scripps Research, La Jolla, CA, USA.
Curtis EngelhartDepartment of Microbiology and Immunology, Weill Cornell Medicine, New York, NY, USA.ORCID 0000-0002-9324-5861
Pradeep KumarNew Jersey Medical School Division of Infectious Disease, Department of Medicine, Rutgers University, Newark, NJ, USA.
Michael B HarbutCalibr-Skaggs Institute for Innovative Medicines, A Division of Scripps Research, La Jolla, CA, USA.
Dongdong LiuCalibr-Skaggs Institute for Innovative Medicines, A Division of Scripps Research, La Jolla, CA, USA.ORCID 0000-0002-7877-5477
Brendan TsudaCalibr-Skaggs Institute for Innovative Medicines, A Division of Scripps Research, La Jolla, CA, USA.ORCID 0009-0009-9661-136X
Bo QinCalibr-Skaggs Institute for Innovative Medicines, A Division of Scripps Research, La Jolla, CA, USA.ORCID 0000-0001-5985-6100
Grant A L BareDepartment of Chemistry, The Scripps Research Institute, La Jolla, CA, USA.ORCID 0000-0003-3446-1633
Gencheng LiDepartment of Chemistry, The Scripps Research Institute, La Jolla, CA, USA.
Victor ChiCalibr-Skaggs Institute for Innovative Medicines, A Division of Scripps Research, La Jolla, CA, USA.
Julian GambacurtaTrudeau Institute, Saranac Lake, NY, USA.
Janine HvizdosTrudeau Institute, Saranac Lake, NY, USA.
Matthew ReaganTrudeau Institute, Saranac Lake, NY, USA.
Isabelle L JonesTrudeau Institute, Saranac Lake, NY, USA.
Lisa M MassoudiMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO, USA.
Lisa K WoolhiserMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO, USA.
Alessandro CascioferroCalibr-Skaggs Institute for Innovative Medicines, A Division of Scripps Research, La Jolla, CA, USA.
Erica KundrickCalibr-Skaggs Institute for Innovative Medicines, A Division of Scripps Research, La Jolla, CA, USA.
Parul SinghNew Jersey Medical School Division of Infectious Disease, Department of Medicine, Rutgers University, Newark, NJ, USA.
William ReileyTrudeau Institute, Saranac Lake, NY, USA.
Thomas R IoergerDepartment of Computer Science, Texas A&M University, College Station, TX, USA.
Dilipkumar Reddy KandulaAB Sciex LLC, Framingham, MA, USA.ORCID 0000-0002-9325-5541
Jacob W McCabeAB Sciex LLC, Framingham, MA, USA.
Taijie GuoInstitute of Translational Medicine, Shanghai Jiao Tong University, Shanghai, China.
David AllandNew Jersey Medical School Division of Infectious Disease, Department of Medicine, Rutgers University, Newark, NJ, USA.
Helena I BoshoffTuberculosis Research Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.ORCID 0000-0002-4333-206X
Dirk SchnappingerDepartment of Microbiology and Immunology, Weill Cornell Medicine, New York, NY, USA.ORCID 0000-0002-4445-7219
Gregory T RobertsonMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO, USA.ORCID 0000-0001-7157-4034
Khisi MdluliGates Medical Research Institute, Cambridge, MA, USA.
Kyoung-Jin LeeCalibr-Skaggs Institute for Innovative Medicines, A Division of Scripps Research, La Jolla, CA, USA.
Jiajia DongInstitute of Translational Medicine, Shanghai Jiao Tong University, Shanghai, China.
Shuangwei LiCalibr-Skaggs Institute for Innovative Medicines, A Division of Scripps Research, La Jolla, CA, USA.
Peter G SchultzCalibr-Skaggs Institute for Innovative Medicines, A Division of Scripps Research, La Jolla, CA, USA.ORCID 0000-0003-3188-1202
Sean B JosephCalibr-Skaggs Institute for Innovative Medicines, A Division of Scripps Research, La Jolla, CA, USA.ORCID 0000-0002-2602-8517
Melissa S LoveCalibr-Skaggs Institute for Innovative Medicines, A Division of Scripps Research, La Jolla, CA, USA.
K Barry SharplessDepartment of Chemistry, The Scripps Research Institute, La Jolla, CA, USA.ORCID 0000-0001-6051-1599
H Michael PetrassiCalibr-Skaggs Institute for Innovative Medicines, A Division of Scripps Research, La Jolla, CA, USA.
Arnab K ChatterjeeCalibr-Skaggs Institute for Innovative Medicines, A Division of Scripps Research, La Jolla, CA, USA.ORCID 0000-0001-5171-7982
James C SacchettiniDepartment of Biochemistry and Biophysics, Texas A&M University, College Station, TX, USA. sacchett@tamu.edu.ORCID 0000-0001-5767-2367
Case W McNamaraCalibr-Skaggs Institute for Innovative Medicines, A Division of Scripps Research, La Jolla, CA, USA. cmcnamara@scripps.edu.ORCID 0000-0002-5754-3407
Funding
Vulnerabilities in Mycobacterial Cell-Wall BiogenesisP01AI095208 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI SACCHETTINI, JAMES C · 2012 to 2022
$19.8MNIAID NIH HHS P01 AI095208
Abstract
Mycobacterium tuberculosis (Mtb) remains the world's deadliest bacterial pathogen
Indexed as
Antitubercular AgentsBacterial ProteinsMycobacterium tuberculosisAnimalsCatalytic DomainCell WallDisease Models, AnimalFemaleHumansMaleMiceMicrobial Sensitivity TestsRatsTuberculosisAntitubercular AgentsBacterial Proteins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.